试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-15
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
编号:NCT04396340登记状态:提前终止企业 / 申办者:Mersana Therapeutics
药物 / 成分:XMT-1592
登记的停止原因(原文):discontinued development program
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-15
Safety and Efficacy of Dexamethasone Ophthalmic Insert (Dextenza®) in the Management of Clinically Significant Dry Eye
编号:NCT04498468登记状态:提前终止企业 / 申办者:Johns Hopkins University
药物 / 成分:Sustained Release Dexamethasone, 0.4 mg、E-Caprolactone-L-Lactide copolymer (PCL) punctal plug
登记的停止原因(原文):The study was terminated prematurely due to administrative reasons; loss of several research personnel. Because of strict eligibility criteria, the investigators anticipated delays in completing enrollment and therefore decided to terminate early.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-15
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
编号:NCT04825860登记状态:提前终止企业 / 申办者:Sumitomo Pharma Co., Ltd.
药物 / 成分:SEP-363856 50 mg、SEP-363856 75 mg、Placebo
登记的停止原因(原文):Due to company business strategy
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-15
A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects
编号:NCT05561530登记状态:提前终止企业 / 申办者:Aligos Therapeutics
药物 / 成分:ALG-125755、Placebo
登记的停止原因(原文):Single doses demonstrated an acceptable safety profile and antiviral activity at all doses evaluated.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
Treatment of Apomorphine-induced Skin Reactions: a Pilot Study
编号:NCT02230930登记状态:提前终止企业 / 申办者:University Medical Center Groningen
药物 / 成分:Apomorphine 0.25% (2.5mg/ml)、Massage with a spiky ball、Hydrocortisone cream 1%、Subcutaneous hydrocortisone 10mg
登记的停止原因(原文):Delayed inclusion - stopped when 10 patients completed the study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma
编号:NCT02451111登记状态:提前终止企业 / 申办者:Swiss Cancer Institute
药物 / 成分:Ibrutinib、Rituximab
登记的停止原因(原文):The premature termination is based on the decision by the SAKK board on November 14, 2020 due to the lack of further financial support for the follow up period.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
编号:NCT02923739登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Bevacizumab、Emactuzumab、Laboratory Biomarker Analysis、Paclitaxel
登记的停止原因(原文):The study was terminated early by the Sponsor
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.
编号:NCT02933801登记状态:提前终止企业 / 申办者:Swiss Cancer Institute
药物 / 成分:ODM-201、Placebo
登记的停止原因(原文):Decision Board no further financial support after 3 years of follow-up as remaining patients in follow-up phase would not relevantly change the endpoints.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
Rucaparib in Nonmetastatic prOstAte With BRCAness
编号:NCT03533946登记状态:提前终止企业 / 申办者:University of Utah
药物 / 成分:Rucaparib
登记的停止原因(原文):New standard of care for study participant population
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
Postoperative Pain Control & Relief in Neonates
编号:NCT03677830登记状态:提前终止企业 / 申办者:St. Louis University
药物 / 成分:Acetaminophen、Saline
登记的停止原因(原文):Involved investigators no longer at the investigating center
查看官方原始记录 ↗